Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Ataluren (PTC124) in Hemophilia A and B
NCT00947193 · PTC Therapeutics · PHASE2 · terminated · last registry update 2020-06-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated early due to Sponsor decision and not reflective of adverse safety findings.” | – | Registry record, PTC Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RPSA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-04-13Results posted on the registry: Eloxx Pharmaceuticals, Inc., ELX-02 (NCT03776539)
- 2021-03-16Results posted on the registry: Eloxx Pharmaceuticals, Inc., ELX-02 + Placebo (NCT03309605)
- 2020-05-27Also stopped (terminated): Eloxx Pharmaceuticals, Inc., ELX-02 (NCT04069260)
- 2019-10-22Also stopped (terminated): Eloxx Pharmaceuticals, Inc., ELX-02 + Placebo (NCT02807961)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision